Program
florensocatib
Also written as “HSK31858, tablet”, “HSK31858” and “HSK31858 tablets”.
Its studies are mostly in Bronchiectasis · Asthma, led by 2 companies.
Drug pageFlorensocatib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 1310 open or running | phase 3since Sep 23, 2024 | Aug 16, 2021 | Nov 2026phase 1 · NCT07915024 |
| Chiesi Farmaceuticiits history only | 33 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | Dec 9, 2026phase 1 · NCT07683793 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Haisco Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 16, 2021First study: phase 1 study in HealthyFirst studyNCT05023525 · 32 enrolled · Australia
- Oct 27, 2022Phase 2 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)NCT05601778 · 226 enrolled · China
- Dec 6, 2022Phase 1 study in Healthy VolunteersNCT05663593 · 74 enrolled · China
- Aug 19, 2024Phase 1 study in HealthyNCT06569784 · 6 enrolled · China
- Sep 23, 2024Phase 3 study in Non-cystic Fibrosis BronchiectasisNCT06660992 · 669 planned · China
- Oct 9, 2024Phase 2 study in AsthmaNCT06637254 · 219 planned · China
- Feb 6, 2025Phase 2 study in BronchiectasisNCT06820749 · 309 planned · China
- Feb 13, 2025Named florensocatibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, HSK31858, CHF10196
- Aug 14, 20252 phase 1 studies in Healthy SubjectsNCT07134478, NCT07134465
- May 23, 2026Phase 3 study in Non-cystic Fibrosis BronchiectasisNCT07616375 · 669 planned · China
- Oct 28, 20263 phase 1 studies in Non-cystic Fibrosis Bronchiectasis (NCFBE)NCT07913009, NCT07915024, NCT07915011
Ahead
- Nov 2026Primary completion: phase 1 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)NCT07915024
- Nov 2026Primary completion: phase 1 study in Non-cystic Fibrosis Bronchiectasis (NCFBE)NCT07915011
- Nov 28, 2026Primary completion: phase 3 study in Non-cystic Fibrosis BronchiectasisNCT06660992
- Nov 30, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07134465
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 Haisco Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915024Non-cystic Fibrosis Bronchiectasis (NCFBE) · China | 1 | Recruiting | Nov 2026 | 47 |
| NCT07915011Non-cystic Fibrosis Bronchiectasis (NCFBE) · China | 1 | Recruiting | Nov 2026 | 24 |
| NCT07913009Non-cystic Fibrosis Bronchiectasis (NCFBE) · China | 1 | Recruiting | Dec 2026 | 30 |
| NCT07616375Non-cystic Fibrosis Bronchiectasis · China | 3 | Recruiting | Jan 10, 2029 | 669 |
| NCT07134478Healthy Subjects · China | 1 | Active, not recruiting | Dec 24, 2024 | 24 |
| NCT07134465Healthy Subjects · China | 1 | By invitation | Nov 30, 2026 | 24 |
| NCT06820749Bronchiectasis · China | 2 | By invitation | Apr 23, 2026 | 309 |
| NCT06637254Asthma · China | 2 | By invitation | Mar 22, 2026 | 219 |
| NCT06660992Non-cystic Fibrosis Bronchiectasis · China | 3 | Recruiting | Nov 28, 2026 | 669 |
| NCT06569784Healthy · China | 1 | Active, not recruiting | Jul 2, 2024 | 6 |
| NCT05663593Healthy Volunteers · China | 1 | Completed | Aug 15, 2022 | 74 |
| NCT05601778Non-cystic Fibrosis Bronchiectasis (NCFBE) · China | 2 | Completed | Mar 29, 2024 | 226 |
| NCT05023525Healthy · Australia | 1 | Completed | Apr 19, 2022 | 32 |
How it is read
Names in the registry
- “HSK31858, tablet”, 4 entries
- “HSK31858”, 3 entries
- “HSK31858 tablets”, 2 entries
- “CHF10196”, 2 entries
- “HSK31858 tablet”, 1 entry
Conditions, from the studies’ own filings
- Bronchiectasis, 8 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.